Efficacy News and Research

RSS

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

A new retrospective study compares the incidence rates of breakthrough infections between different time points at which individuals were vaccinated.

5 Aug 2021

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

In a recently published article in The New England Journal of Medicine, scientists have described how multi-mutational variants of SARS-CoV-2 may evolve in patients with immunosuppression.

5 Aug 2021

Mobile apps can help promote physical activity during COVID-19 lockdown

Gyms and sporting clubs might close, and lockdown conditions make it difficult to exercise, but people are urged to take the next step and download fitness apps to keep moving.

5 Aug 2021

Contingency management at end-of-treatment helps to overcome opioid use disorder

The opioid epidemic remains a U.S. public health crisis and has only worsened since the COVID-19 pandemic began in 2020, with opioid deaths accounting for 69,000 of 93,000 overdose-related deaths in 2020, according to provisional drug overdose data released by the U.S. Centers for Disease Control and Prevention in July 2021.

5 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

K-State research team aims to improve immunotherapy treatment for cancer patients

Immunotherapy can leverage the body's immune system to fight cancer. While excellent responses have been observed for some patients, a considerably larger number have received little benefit.

4 Aug 2021

Non-invasive brain stimulation may reduce smoking frequency in nicotine-dependent smokers

A new systematic review of randomized controlled trials has found evidence that non-invasive brain stimulation may reduce smoking frequency (number of cigarettes per day) in nicotine-dependent smokers.

4 Aug 2021

Initiating therapeutic anticoagulation benefits moderately ill COVID-19 patients, but not critically ill patients

A large clinical trial conducted worldwide shows that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances of leaving the hospital.

4 Aug 2021

Artificial pancreas may soon help patients with type 2 diabetes

An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis. Tests led by the University of Cambridge and Inselspital, University Hospital of Bern, Switzerland, show that the device can help patients safely and effectively manage their blood sugar levels and reduce the risk of low blood sugar levels.

4 Aug 2021

Research documents the existing models of care for patients with opioid use disorder

Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).

4 Aug 2021

Investigational treatment improves survival rate of babies lacking thymus

An investigational treatment pioneered by a Duke Health pediatrician resulted in a one-year survival rate of 77% among children born with a rare condition in which they lack an immune system.

4 Aug 2021

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Scientists from Germany and Italy recently demonstrated the benefits of intramuscular/intranasal heterologous prime-boost vaccination regimen against coronavirus disease 2019 (COVID-19).

4 Aug 2021

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; "Rigaku"), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”)

From Rigaku Corporation 4 Aug 2021

Researchers develop nanofibrous filters that can capture and kill airborne coronaviruses under visible light irradiation

A new study discusses the development of photosensitized electrospun nanofibrous membranes capable of capturing and inactivating SARS-CoV-2 aerosols.

4 Aug 2021

One billion doses of Oxford-AstraZeneca COVID-19 vaccine released

The University of Oxford's and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca's joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

4 Aug 2021

The Four Cs which could affect people’s willingness to get vaccinated

The changing advice around the AstraZeneca vaccine and months of zero COVID cases in the Australian community has led to one of Australia’s biggest challenges: how to get enough people to get vaccinated.

4 Aug 2021

Factors affecting SARS-CoV-2 transmission and outbreak control in densely populated areas

A new study seeks to identify the factors that lead to enhanced SARS-CoV-2 transmission and the effects of control measures, in a dormitory in Singapore.

3 Aug 2021

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

A recent study from the University of Rochester reveals how the biodistribution kinetics and the affinity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for many different organs in the human body can be affected by antibodies targeting viral spike glycoprotein. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Discovery may enable the development of new therapies to kill aggressive cancer cells

Vanderbilt faculty and researchers are looking for the "Achilles' heel" of the cancer cells that survive initial chemotherapy.

3 Aug 2021

Efficacy News and Research

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

Mobile apps can help promote physical activity during COVID-19 lockdown

Contingency management at end-of-treatment helps to overcome opioid use disorder

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

K-State research team aims to improve immunotherapy treatment for cancer patients

Non-invasive brain stimulation may reduce smoking frequency in nicotine-dependent smokers

Initiating therapeutic anticoagulation benefits moderately ill COVID-19 patients, but not critically ill patients

Artificial pancreas may soon help patients with type 2 diabetes

Research documents the existing models of care for patients with opioid use disorder

Investigational treatment improves survival rate of babies lacking thymus

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Researchers develop nanofibrous filters that can capture and kill airborne coronaviruses under visible light irradiation

One billion doses of Oxford-AstraZeneca COVID-19 vaccine released

The Four Cs which could affect people’s willingness to get vaccinated

Factors affecting SARS-CoV-2 transmission and outbreak control in densely populated areas

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

“Sybodies” protect against SARS-CoV-2 in hamster model

Discovery may enable the development of new therapies to kill aggressive cancer cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News